Sanofi said it will stop a Phase 3 trial of riliprubart in a rare neurological disorder after an independent committee determined the study was unlikely to show sufficient efficacy. The decision ends one late-phase development opportunity and adds to the company’s pipeline challenges. The company framed the move as tied to the committee’s assessment of interim results. The setback reflects the risk profile of antibody programs in rare neurodegenerative areas, where endpoint sensitivity and effect sizes can be hard to demonstrate. The immediate implication is that Sanofi will have to redeploy resources and re-balance its late-stage portfolio in advance of upcoming readouts. For investors and partners, stopping a Phase 3 program typically accelerates external partnering discussions on adjacent targets and may shift competitive dynamics in the same disorder space.